¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"neoplasms, germ cell and embryonal"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • eosinophilic cell
    È£»ê¼¼Æ÷
  • ependymal cell
    ³ú½Ç¸·¼¼Æ÷
  • epidermal cell
    Ç¥ÇǼ¼Æ÷
  • epithelial cell
    »óÇǼ¼Æ÷
  • epithelioid cell
    »óÇǸð¾ç¼¼Æ÷
  • epithelioid cell nevus
    »óÇǸð¾ç¼¼Æ÷¸ð¹Ý
  • erythroid cell
    ÀûÇ÷±¸
  • established cell line
    È®¸³¼¼Æ÷ÁÖ
  • ethmoidal air cell
    ¹úÁý, »ç°ñºÀ¼Ò
  • ethmoidal cell
    ¹úÁý, »ç°ñºÀ¼Ò
  • eukaryotic cell
    ÁøÇÙ¼¼Æ÷
  • fat cell
    Áö¹æ¼¼Æ÷
  • fat-storing cell
    Áö¹æÀúÀå¼¼Æ÷
  • flagellated cell
    Æí¸ð¼¼Æ÷
  • flame cell
    ºÒ²É¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • differentiated cell
    ºÐÈ­¼¼Æ÷
  • diploid cell
    µÎ¹è¼öü¼¼Æ÷
  • duct cell carcinoma
    °ü¼¼Æ÷¾ÏÁ¾
  • dust cell
    ¸ÕÁö¼¼Æ÷
  • effector cell
    ÀÛµ¿¼¼Æ÷
  • egg cell
    ³­¼¼Æ÷, ¾Ë¼¼Æ÷
  • endothelial cell
    ³»ÇǼ¼Æ÷
  • enterochromaffine cell
    âÀÚģũ·Ò¼¼Æ÷, âÀÚÅ©·Òģȭ¼¼Æ÷
  • eosinophilic cell
    È£»ê¼¼Æ÷
  • ependymal cell
    ³ú½Ç¸·¼¼Æ÷
  • epidermal cell
    Ç¥ÇǼ¼Æ÷
  • epithelial cell
    »óÇǼ¼Æ÷
  • epithelioid cell
    »óÇǸð¾ç¼¼Æ÷
  • erythroid cell
    (¢¡red blood cell) ÀûÇ÷±¸
  • ethmoidal cell
    ¹úÁý»À¹úÁý, »ç°ñºÀ¼Ò
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • amacrine cell
    ¾Æ¸¶Å©¸° ¼¼Æ÷
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
  • aneuploid cell
    À̼ö¼º¼¼Æ÷
  • anitschkow cell
    ¾Æ´ÏÄ¡ÄÚ¿ì¼¼Æ÷(¡­á¬øà)
  • annular elastotic giant cell granuloma
    ȯ»ó ź·Â ¼¶À¯¼º °Å´ë¼¼Æ÷ À°¾ÆÁ¾
  • anoxic cell
    ¹«»ê¼Ò¼¼Æ÷
  • anti-idiotypic T suppressor cell
    Ç×°³º°Æ¯ÀÌÇü ¾ïÁ¦T¼¼Æ÷
  • antibody dependent cell mediated cytotoxicity
    Ç×üÀÇÁ¸ ¼¼Æ÷¸Å°³ ¼¼Æ÷µ¶¼º.
  • antibody forming cell
    Ç×ü»ý»ê¼¼Æ÷(ù÷ô÷ßæß§á¬øà).
  • antibody producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antigen presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷.
  • antigen reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷.
  • apex of cell
    ¼¼Æ÷²À´ë±â
  • apical cell
    Á¤(´Ü)¼¼Æ÷(ð¢Ó®á¬øà)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • personality, anxious and fearful
    ºÒ¾È°øÆ÷¼º ÀΰÝ
  • pharmacy and therapeutic committee
    ¾à»çÀÇ·áÀ§¿øÈ¸(ËâË×ËöËíËôËôÌ·) º´¿ø(ËÓ Ëô)ÀÇ .
  • pneumocyte, types i and ii
    ÆóÆ÷¼¼Æ÷(øËøàá¬øà), IÇü°ú IIÇü
  • porokeratotoic eccrine ostial and dermal duct nevus
    ÇѰø°¢È­Áõ¼º ¿¡Å©¸°±¸¸Û ¹× ÁøÇǰü¸ð¹Ý
  • positional and postural vertigo
    µÎÀ§ ¹× üÀ§ º¯È¯(¼º) Çö±â
  • positive and expiratory pressure
  • pruritic urticarial papules and plaqes of pregnany
    ÀӽŠ¼Ò¾ç¼º µÎµå·¯±â¼º ±¸Áø ¹× ÆÇ
  • pseudoepitheliomatous keratotic and micaceous balanitis
    °¡¼º»óÇÇÁ¾¼º ¼®¸é°¢È­ ±ÍµÎ¿°
  • pulmonary congestion and edema
    Æó¿ïÇ÷(øËê¦úì) ¹× ÆóºÎÁ¾(øËÝ©ðþ)
  • regions and parts of body
    ¸ö ºÎÀ§ ¹× ºÎºÐ
  • release of information and confidentiality
    Á¤º¸¿Í ºñ¹Ð´©¼³(ÝúÚËÒèàÜ)
  • right and left lobe
    ¿À¸¥¿±°ú ¿Þ¿±, ¿ì¿±°ú Á¿±(éÓ稡­ñ§ç¨).
  • right and left margin of uterus
    ¿À¸¥¡¤¿ÞÀڱð¡ÀåÀÚ¸®, Á¿ìÀڱÿ¬(ñ§éÓí­
  • sacral nerves and coccygeal nerve
    ¾ûÄ¡½Å°æ ¹× ²¿¸®½Å°æ
  • salt and pepper appearance
    ¼Ò±Ý ÈÄÃß°¡·ç ¸ð¾ç
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • Hair cell
    Åм¼Æ÷
    [¿¾ ¿ë¾î] À¯¸ð°¨°¢¼¼Æ÷
  • Juxtaglomerular cell
    Å丮°ç¼¼Æ÷
    [¿¾ ¿ë¾î] »ç±¸Ã¼¹æ¼¼Æ÷
  • Flagellated epithelial cell
    Æí¸ð»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Æí¸ð»óÇǼ¼Æ÷
  • Squamous epithelial cell
    ÆíÆò»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ÆíÆò»óÇǼ¼Æ÷
  • Squamous cell
    ÆíÆò¼¼Æ÷
    [¿¾ ¿ë¾î] ÆíÆò¼¼Æ÷
  • Phagocytic synovial cell
    Æ÷½ÄÀ±È°¼¼Æ÷
    [¿¾ ¿ë¾î] Ȱ¸·½Ä¼¼Æ÷
  • Superficial cell
    Ç¥¸é»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ÀåÇ¥¸é¼¼Æ÷
  • Superficial epithelial cell
    Ç¥¸é»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Ç¥¸é»óÇǼ¼Æ÷
  • Superficial epithelial cell
    Ç¥¸é»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Ç¥Ãþ»óÇǼ¼Æ÷
  • Surface epithelial cell
    Ç¥¸é»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Ç¥¸é»óÇǼ¼Æ÷
  • Superficial epithelial cell
    Ç¥¸é¼¼Æ÷
    [¿¾ ¿ë¾î] õ»óÇǼ¼Æ÷
  • Pyramidal cell
    ÇǶó¹Ô¼¼Æ÷
    [¿¾ ¿ë¾î] Ãßü¼¼Æ÷
  • Mesangial cell
    Ç÷°ü»çÀ̼¼Æ÷
    [¿¾ ¿ë¾î] Ç÷°ü°£¼¼Æ÷
  • Intravascular giant cell
    Ç÷°ü¼Ó°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] Ç÷°ü³»°Å´ë¿µ¾ç¸·¼¼Æ÷
  • [Pluripotential hemopoietic stem cell]
    Ç÷±¸¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] Ç÷±¸¸ð¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
CI cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar...
CMI carbohydrate metabolism index; care management integration; case mix index; cell-mediated immunity; ...
CML carboxymethyl lysine; cell-mediated lymphocytotoxicity; cell-mediated lympholysis; central motor lat...
FDC factor-dependent cell [line]; follicular dendritic cell
GPC gastric parietal cell; gel permeation chromatography; giant papillary conjunctivitis; glycophorin C;...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
P(i) phosphate and inorganic phosphate
A and
APACHE ACUTE PHYSIOLOGY AND CHRONIC HEALTH EVALUATION
ADME Absorption, distribution, metabolism, and excretion
APD(90) Action potential duration at 50% and 90
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell mediated lympholysis
    ¼¼Æ÷ ¸Å°³ ¸²ÇÁ±¸ ¿ëÇØ
  • cell mediated reaction
    ¼¼Æ÷ ¸Å°³¼º ¹ÝÀÀ
  • cell membrane permeability
    ¼¼Æ÷¸· Åõ°ú¼º
  • cell of parathyroid gland
    ºÎ°©»ó»ù ¼¼Æ÷, ºÎ°©»ó¼± ¼¼Æ÷
  • cell organelles
    ¼¼Æ÷ ¼Ò±â°ü
  • cell physiology
    ¼¼Æ÷ »ý¸®ÇÐ
  • cell pole
    ¼¼Æ÷ ±Ø
  • cell regeneration
    ¼¼Æ÷ Àç»ý
  • cell saver
    Ç÷±¸ ȸ¼ö±â
  • cell sorting
    ¼¼Æ÷ ºÐ·ù
  • cell substitution
    ¼¼Æ÷ ġȯ, Ç÷±¸ Àç»ý
  • cell surface marker
    ¼¼Æ÷ Ç¥¸é Ç¥ÁöÀÚ
  • cell survival curve
    ¼¼Æ÷ »ýÁ¸ °î¼±
  • cell transfer
    ¼¼Æ÷ ÀÌÀÔ
    Á¼Àº Àǹ̿¡¼­´Â °¢Á¾ ¼¼Æ÷¸¦ ¹æ»ç¼± Á¶»ç µîÀÇ Ã³¸®¸¦ °¡ÇÑ µ¿¹°¿¡ ÁÖÀÔÇϰí ÁÖÀÔµÈ ¼¼Æ÷ÀÇ ¼º»óÀ» Á¶»çÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ ¼¼Æ÷ ÁÖÀÔÀÇ ¹æ¹ýÀ» °¡¸®Å°¸ç in vitro¿¡¼­ ¼¼Æ÷ ±â´ÉÀ» Á¶»çÇϱⰡ °ï¶õÇÑ °æ¿ì, in vivo¿¡¼­ÀÇ ¹ÝÀÀ¼ºÀ» Á¶»çÇÏ°í ½ÍÀº °æ¿ì, ¶Ç chimera mouse¸¦ Á¦ÀÛÇÒ ¶§¿¡ »ç¿ëµÈ´Ù. ³ÐÀº Àǹ̿¡¼­´Â ¼¼Æ÷°¡ ÇÑÆí¿¡¼­ ´Ù¸¥ ÆíÀ¸·Î À̵¿ÇÏ´Â °ÍÀ» °¡¸®Å²´Ù.
  • cell typing
    Ç÷±¸Çü °Ë»ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
maintenance and engineering, hospital Hospital department whose primary function is the upkeep and supervision of the buildings and grounds and the maintenance of hospital physical plant and equipment which requires engineering expertise.
(12 Dec 1998)
P and P test A test formerly used by some to control anticoagulant therapy with bishydroxycoumarin and indandione drugs.
Synonym: P and P test.
(05 Mar 2000)
malignancy and immunodeficiency <radiology> High risk of malignancy (especially lymphoma/leukaemia, GI tumours): X-linked agammaglobulinaemia (Bruton's), common variable immunodeficiency, severe combined immunodeficiency (SCID kids), ataxia-telangectasia, Wiscott-Aldrich syndrome, selective IgA deficiency
(12 Dec 1998)
Papillon-Leage and Psaume syndrome <syndrome> An inherited syndrome, lethal in males, with varying combinations of defects of the oral cavity, face, and hands, including lobulated or bifid tongue, cleft or pseudocleft palate, tongue tumours, missing or malpositioned teeth, hypoplastic nasal alar cartilage, depressed nasal bridge, brachydactyly, clinodactyly, incomplete syndactyly, and, frequently, mental retardation.
There are two subtypes recognised. Type I (papillon-leage and psaume syndrome, gorlin-psaume syndrome) is inherited as an x-linked dominant trait and is found only in females and XXY males. Type II (mohr syndrome) is inherited as an autosomal recessive trait.
Inheritance: autosomal recessive and X-linked.
Synonym: OFD syndrome, orofaciodigital syndrome, Papillon-Leage and Psaume syndrome.
(05 Mar 2000)
Gell and Coombs Classification A classification system that differentiates the 4 types of hypersensitivity reactions: Type I: anaphylactic reactions, Type II: cytotoxic reactions, Type III: immune complex reactions, and Type IV: cell-mediated reactions.
(05 Mar 2000)
rate setting and review A method of examining and setting levels of payments.
(12 Dec 1998)
ratio of decayed and filled surfaces An index of decayed and filled permanent surfaces per person, per full complement of 122 tooth surfaces.
(05 Mar 2000)
ratio of decayed and filled teeth An index of decayed and filled permanent teeth per person, per full complement of 28 teeth.
(05 Mar 2000)
receptors, cytoplasmic and nuclear Proteins in the cytoplasm or nucleus that specifically bind signalling molecules and trigger changes which influence the behaviour of cells. The major groups are the steroid hormone receptors, which usually are found in the cytoplasm, and the thyroid hormone receptors, which usually are found in the nucleus. Receptors, unlike enzymes, generally do not catalyze chemical changes in their ligands.
(12 Dec 1998)
maternal age 35 and over Pregnancy in women 35 or more years of age. It is used for normal pregnancies and for problems of pregnancy occurring in a woman's late reproductive years. These include effects on the mother's physical and mental health as well as risks of perinatal mortality and foetal abnormality.
(12 Dec 1998)
VH and VL genes/domains VH and VL genes define in part the sequences of the variable heavy and light regions of immunoglobulin molecules. VH and VL domains are the regions of amino acid sequence so defined. J genes and, in the case of the heavy chain, a D gene (D=diversity) also define these regions. Gene rearrangement also plays a role in determining the sequences in which the genes are joined as the DNA of the immunoglobulin producing cell matures.
(18 Nov 1997)
referral and consultation The practice of sending a patient to another program or practitioner for services or advice which the referring source is not prepared to provide.
(12 Dec 1998)
measles, mumps and rubella vaccine A combination of live attenuated measles, mumps, and rubella viruses in an aqueous suspension; used for immunization against the respective diseases.
(05 Mar 2000)
rehabilitation of speech and language disorders Procedures for assisting a person with a speech or language disorder to communicate with maximum efficiency.
(12 Dec 1998)
patient credit and collection Accounting procedures for determining credit status and methods of obtaining payment.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • smash and grab
    °¡°ÔÀÇ Áö³ç¤©´çÀ» ºÎ¼ö°í °í°¡ÀÇ Áø¿­Ç°À» ¼ø½Ä°£¿¡ »©¾Ñ¾Æ°¡´Â;±×·¯ÇÑ °­µµ;Áø¿­Ã¢ °­µµ
  • tip-and-run
    Àü°ÝÀûÀÎ
  • touch-and-go
    ¾Æ½½¾Æ½½ÇÑ(»óÅÂ)
  • track and field
    À°»ó°æ±â
  • wash-and-wear
    (Á÷¹°ÀÌ) ¼¼Å¹ÈÄ ´Ù¸®Áö ¾Ê°í ÀÔÀ» ¼ö ÀÖ´Â
  • young and all
    ´©±¸³ª ¸ðµÎ;Àü¿ø
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
ÅëÇÕ°Ë»ö ¿Ï·á